Human papillomavirus (HPV) is the infectious cause of cervical cancer, one of the leading causes of cancer and cancer-related deaths in women worldwide. Large numbers of women in the US each year are referred to colposcopy / biopsy for abnormal Pap tests and/or positive HPV DNA tests for cervix cancer prevention, however the majority will not have precancerous lesions. Because HPV vaccination will not help everyone and does not prevent all cervical cancer, screening will be needed for the foreseeable future. Thus, there is a critical need to improve the accuracy of cervical cancer screening in general, and the specificity of HR-HPV DNA testing, in particular, to reduce the harms of screening. In this competitive renewal, we will expand upon our recent reports showing that oncogenic HPV epigenetic methylation patterns for HPV16, 18, 31 and 45 have high sensitivity / specificity for detection of prevalent histologically confirmed cervical intraepithelial neoplasia grade 3 or more severe (CIN3+). In other studies, we have defined the genetic heterogeneity of the HPV16-related HR-types (HPV31, 33, 35, 52, 58), established a nomenclature for variant lineages, and shown that HR-HPV variants have different risks for persistence and progression. Overall, our data provide evidence that determining the epigenetic and genetic factors that underlie HPV carcinogenicity is important not only scientifically, but also to enhance and improve screening. Based on the data from this application, we envision a scenario where a HR-HPV DNA+ test could be reflex tested for HR-HPV variant / methylation status. In addition, emerging data implicate the microbiome as a risk factor for a variety of cancers. We have embraced new technology to characterize the cervicovagnial microbiome (CMB) and hypothesize that the CMB is an important determinant explaining, in part, the small minority of HR-HPV infections that do not resolve, but progress to precancer and cancer. We propose to use 4 large, well-characterized NCI cohorts with a total of >2000 histologically confirmed CIN3+ cases to: (1) determine the associations of HR-HPV viral CpG methylation with CIN3+, we will perform case-control studies to evaluate methylation at CpG sites using pyrosequencing and an innovative Next-Gen sequencing protocol of bisulfite treated samples;(2) study the temporal process of HPV genome methylation that precedes and predicts development of incident CIN3+, we will perform a longitudinal study. We will determine the percent methylation as a function of time prior to diagnosis;(3) study the nucleotide variations in HR-HPV genomes associated with risk of precancer/cancer, we will analyze both lineage and variant sites using case-control studies. We will use systems biology approaches and phylogenomics to characterize the genomic determinants of HPV oncogenicity;and, (4) examine the CMB as a cofactor in progression of HR- HPV infections to CIN3, we will determine the microbiome using our recently published methods that employ barcoded primers to the 16S ribosomal RNA gene, Next-Gen sequencing, and a bioinformatics pipeline.
Cervical cancer is one of the top 4 causes of cancer and cancer-related deaths in women worldwide and is caused by a high-risk human papillomavirus (HR-HPV) infection of the cervix. Cervix cancer can be prevented by Pap smear testing and/or HR-HPV detection to identify women with precancerous lesions that can be treated. This study will investigate novel markers on the human papillomavirus genome and in the cervical environment (cervical microbiome) that have the potential to identify HR-HPV infected women at greatest risk for cervix cancer that can be treated, while preventing women at lower risk from having an invasive procedure.
|Chen, Alyce A; Heideman, Danielle A M; Boon, Debby et al. (2014) Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology 448:356-62|
|Chan, Paul K S; Zhang, Chuqing; Park, Jong-Sup et al. (2013) Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. Int J Cancer 132:2528-36|
|Mbulaiteye, S M; Kemp, T; Gage, J C et al. (2013) Plasma cytokine levels and human papillomavirus infection at the cervix in rural Nigerian women. Cytokine 64:146-51|
|Ajenifuja, Kayode Olusegun; Gage, Julia C; Adepiti, Akinfolarin C et al. (2013) A population-based study of visual inspection with acetic acid (VIA) for cervical screening in rural Nigeria. Int J Gynecol Cancer 23:507-12|
|Gage, Julia C; Ajenifuja, Kayode O; Wentzensen, Nicolas A et al. (2012) The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer 130:2111-7|
|Mirabello, Lisa; Sun, Chang; Ghosh, Arpita et al. (2012) Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 104:556-65|
|Rodríguez, Ana Cecilia; García-Piñeres, Alfonso J; Hildesheim, Allan et al. (2011) Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. Int J Cancer 128:597-607|
|Schiffman, Mark; Rodriguez, Ana Cecilia; Chen, Zigui et al. (2010) A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70:3159-69|
|Van Doorslaer, Koenraad; Burk, Robert D (2010) Evolution of human papillomavirus carcinogenicity. Adv Virus Res 77:41-62|
|Wang, Sophia S; Gonzalez, Paula; Yu, Kai et al. (2010) Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One 5:e8667|
Showing the most recent 10 out of 50 publications